Abstracts tagged "axial spondyloarthritis"

Abstract Number: 675 • 2016 ACR/ARHP Annual Meeting
Association Between Structural Lesions in the Sacroiliac Joints and Spinal Inflammatory Lesions in Patients with Non-Radiographic Axial Spondyloarthritis
Maxime Dougados¹, Robert G Lambert², Stephanie Wichuk³, Jean-Claude Becker⁴, Jack F Bukowski⁵, Heather Jones⁶, Lisa Marshall⁶, Annette Szumski⁷ and Walter Maksymowych³, ¹Rheumatology, Paris Descartes University, Paris, France, ²Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ³Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Becker Clinical Research Consulting, New York, NY, ⁵Clinical Affairs, Pfizer, Collegeville, PA, ⁶Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁷inVentiv Health, Princeton, NJ
Background/Purpose: The relevance of structural lesions in non-radiographic axial SpA (nr-axSpA) is unclear, particularly without signs of MRI inflammation. In a post hoc analysis we…
Abstract Number: 2740 • 2016 ACR/ARHP Annual Meeting
Cam Type Femoroacetabular Impingement Morphology Is More Frequent in Patients with Axial Spondyloarthritis
Servet Akar¹, Ozgur Tosun², Dilek Solmaz³, Gokay Karaca², Aliye Tosun⁴, Mustafa Ozman⁵ and Fatih Esat Topal⁶, ¹Department of Rheumatology, İzmir Katip Çelebi University, School of Medicine, İzmir, Turkey, İzmir, Turkey, ²Radiology, Izmir Katip Celebi University School of Medicine, izmir, Turkey, ³Rheumatology, Izmir Katip Celebi University School of Medicine, izmir, Turkey, ⁴physical therapy and rehabilitation, Izmir Katip Celebi University School of Medicine, izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁶Emergency Medicine, Izmir Katip Celebi University School of Medicine, Izmir, Turkey
Background/Purpose: Femoroacetabular impingement (FAI) is characterized by early pathologic contact of the proximal femur with the acetabulum. Pincer impingement is the acetabular cause of FAI.Whereas…
Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Juergen Braun⁴, Gustavo Citera⁵, Filip van Den Bosch^6,7, Ronald Pedersen⁸, Randi Bonin⁹, Heather Jones¹⁰, Lisa Marshall¹⁰, Sameer Kotak¹¹, Isabelle Logeart¹², Bonnie Vlahos¹³, Jack F Bukowski⁹ and Walter Maksymowych¹⁴, ¹Rheumatology Department, Hôpital Cochin, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹Clinical Affairs, Pfizer, Collegeville, PA, ¹⁰Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Medical Affairs, Pfizer, France, Paris, France, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting
Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Matthew A. Brown¹, Paul A. Bird², Philip C. Robinson³, Philip J. Mease⁴, Filip van Den Bosch⁵, Christine Surian⁶, Zirke Wiid⁶, Heather Jones⁷, Annette Szumski⁸ and Lisa Marshall⁷, ¹Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²University of New South Wales, Sydney, Australia, ³University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Pfizer Australia, Sydney, Australia, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
Abstract Number: 976 • 2015 ACR/ARHP Annual Meeting
The Reason of Discontinuation of a First TNF Inhibitor Affects Drug Retention of a Second Anti-TNF Agent in Axial Spondyloarthritis
Adrian Ciurea¹, Pascale Exer², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Beate Steininger¹, Rudolf O. Kissling⁶, Jürg Bernhard⁷ and Almut Scherer⁸, ¹Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Private rheumatology practice, Basel, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology, University Hospital, Zurich, Switzerland, ⁶Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁷Rheumatology and Rehabilitation, Bürgerspital Solothurn, Solothurn, Switzerland, ⁸SCQM Foundation, Zurich, Switzerland
Background/Purpose: Conflicting results have been demonstrated in axial spondyloarthritis (axSpA) with regard to whether effectiveness of a second (2°) TNFi depends on the reason of…
Abstract Number: 1231 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Non-Radiographic Axial Spondyloarthritis Among Patients with Inflammatory Back Pain in Rheumatology Practices
Rubén Burgos-Vargas¹, James Wei², Mahboob U Rahman³, Nurullah Akkoc⁴, Syed A. Haq⁵, Mohammed Hammoudeh⁶, Ehab Mahgoub⁷, Ena Singh⁸, Lyndon Llamado⁹, Khalid Shirazy¹⁰, Sameer Kotak¹¹, Connie Hammond⁷, Ronald Pedersen¹², Qi Shen¹³ and Bonnie Vlahos¹³, ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, ³Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁴Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁵Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, ⁶Medicine, Hamad Medical Corporation, Doha, Qatar, ⁷Pfizer, Collegeville, PA, ⁸500 Arcola Road, Pfizer, Collegeville, PA, ⁹Pfizer, Makati, Philippines, ¹⁰Pfizer, Dubai, United Arab Emirates, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Department of Biostatistics, Pfizer, Collegeville, PA, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA
Background/Purpose: The diagnosis of Ankylosing Spondylitis (AS) is delayed by >10 years after the symptoms develop, as by definition the modified NY criteria for classification…
Abstract Number: 1283 • 2015 ACR/ARHP Annual Meeting
The Burden of Non-Radiographic Axial Spondyloarthritis from the Employer Perspective: A Real World European Study
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) is a burdensome disease to both the patient and the healthcare system, as previous research has indicated. However, the societal…
Abstract Number: 1284 • 2015 ACR/ARHP Annual Meeting
Burden of Illness Associated with Non-Radiographic Axial Spondyloarthritis: A European Real World Database Analysis from the Clinical and Healthcare System Perspective
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Whilst the burden of axial spondyloarthritis (axSpA) is well known, non-radiographic (nr)-axSpa has only recently been identified as a distinct spondyloarthritic indication with its…
Abstract Number: 2025 • 2015 ACR/ARHP Annual Meeting
Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Walter Maksymowych¹, Stephanie Wichuk², Maxime Dougados³, Heather Jones⁴, Annette Szumski⁵, Lisa Marshall⁴, Jack F Bukowski⁶ and Robert G Lambert⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology Research Lab, University of Alberta, Edmonton, AB, Canada, ³Rheumatology Department, Hôpital Cochin, Paris, France, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC)…
Abstract Number: 2298 • 2015 ACR/ARHP Annual Meeting
Misdiagnosis of Fibromyalgia (FM) As Axial Spondylarthritis (SpA): Lessons from Analysis of 26 Cases
Dongfeng Liang, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: Both patients with fibromyalgia (FM) and with axial spondyloarthritis (SpA) are suffering from pain. The patients with axial SpA are mainly manifested as inflammatory…
Abstract Number: 2629 • 2015 ACR/ARHP Annual Meeting
The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire
Laure Gossec^1,2, Pierre Chauvin^3,4, Christophe Hudry⁵, Florence Mathoret-Philibert⁶, Maud Poussière⁷, Thibault de Chalus⁸, Francoise Russo-Marie⁹, Jean-Michel Joubert⁸, Alain Saraux¹⁰ and Francis Berenbaum^1,11, ¹Rheumatology Department, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ²Rheumatology Department, AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Department of Social Epidemiology, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ⁴Department of Social Epidemiology, Pierre Louis Institute of Epidemiology and Public Health, Paris, France, ⁵Rheumatology, AP-HP, Hôpital Cochin, Paris, France, ⁶Clinical Psychology Department, AP-HP, Hôpital Cochin, Paris, France, ⁷Independent Researcher, Paris, France, ⁸UCB Pharma, Colombes, France, ⁹Arthritis Foundation Courtin, Neuilly-sur-Seine, France, ¹⁰Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹¹Rheumatology Department, AP-HP, Hôpital Saint-Antoine, Paris, France
Background/Purpose: Patients with chronic inflammatory disorders such as rheumatoid arthritis (RA) or spondyloarthritis (SpA) create personal sets of fears and beliefs related to their disease.…
Abstract Number: 2632 • 2015 ACR/ARHP Annual Meeting
Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases
Laure Gossec^1,2, Alain Saraux³, Christophe Hudry⁴, Florence Mathoret-Philibert⁵, Maud Poussière⁶, Thibault de Chalus⁷, Francoise Russo-Marie⁸, Jean-Michel Joubert⁷, Pierre Chauvin⁹ and Francis Berenbaum^1,10, ¹Rheumatology Department, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ²Rheumatology Department, AP-HP, Hôpital Pitié Salpêtrière, Paris, France, ³Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁴Rheumatology, AP-HP, Hôpital Cochin, Paris, France, ⁵Clinical Psychology Department, AP-HP, Hôpital Cochin, Paris, France, ⁶Independent Researcher, Paris, France, ⁷UCB Pharma, Colombes, France, ⁸Arthritis Foundation Courtin, Neuilly-sur-Seine, France, ⁹Department of Social Epidemiology, Sorbonne Universités, Université Pierre et Marie Curie, Paris, France, ¹⁰Rheumatology Department, Hôpital Saint-Antoine, Paris, France
Background/Purpose: Questionnaires assessing the beliefs of patients with chronic rheumatic diseases mainly focus on medications.1A validated questionnaire evaluating patients' fears and beliefs towards their disease…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 2812 • 2015 ACR/ARHP Annual Meeting
Cytokine Secretion By Peripheral Blood Mononuclear Cells in Patients with Axial Spondyloarthritis and the Effect of Thymoquinone on Cytokine Profile
Erkan Kilic¹, Cagri Sakalar², Huriye Aksu³, Mustafa Cakir³, Gamze Kilic¹ and Salih Ozgocmen⁴, ¹Dept. PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey, ²Genome and Stem Cell Center (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, ³Genome and Stem Cell Senter (GEN-KOK), Erciyes University, Faculty of Medicine, Medical Biology, Kayseri, Turkey, ⁴Dept.PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) defines a group of chronic inflammatory diseases which includes non-radiographic axSpA (nr-axSpA) who do not have definite sacroiliitis on pelvic X-rays.…
Abstract Number: 663 • 2015 ACR/ARHP Annual Meeting
Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].